Cortex to Hold Conference Call on October 26 Following Release of CX717 from FDA Clinical Hold.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :COR) received the formal letter from the U.S. Food and Drug Administration on Monday, October 23, 2006 regarding the lifting of the clinical hold on CortexeIUs lead product candidate, AMPAKINEE1/2 CX717. The Company will host a conference call at 4:00 p.m. ET (1:00 p.m. PT) on Thursday, October 26th to review the steps it is taking to advance the development of CX717. Those who wish to participate may do so by dialing 1-877-407-0782 in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and 201-689-8567 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 1-877-660-6853 for participants in the United States and 1-201-612-7415 for international participants and entering account number 286 and conference ID 218465 when prompted. About Cortex Pharmaceuticals Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in AlzheimereIUs disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the braineIUs neurotransmitter neurotransmitter, chemical that transmits information across the junction (synapse) that separates one nerve cell (neuron) from another nerve cell or a muscle. Neurotransmitters are stored in the nerve cell's bulbous end (axon). system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , AlzheimereIUs disease and anxiety disorders Anxiety disorders A group of distinct psychiatric disorders characterized by marked emotional distress and social impairment, including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and posttraumatic stress disorder. . (http://www.cortexpharm.com/) Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. Note eI This press release contains forward-looking statements concerning the CompanyeIUs research and development activities. The success of such activities depends on a number of factors, including the risks that CX717, or the CompanyeIUs other proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical testing and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the CompanyeIUs Securities and Exchange Commission filings, the CompanyeIUs proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion